Brigatinib, another highly selective ALK TKIs with a 12-fold stronger potent against ALK than crizotinib, has been widely applied in patients with regressive ALK-positive metastatic NSCLC or resistant to crizotinib. Here, ALK is linked to non-small cell lung carcinoma.